Studienlage · Detail
Use of Cannabis for Self-Management of Chronic Pelvic Pain
Gemischt
53 Zitate
Stichproben = 274
DauerMärz bis August 2019
EndpunktPrävalenz der Cannabisnutzung
Verblindungn.a.
DesignSonstiges
Kernaussage
96% der Cannabis-Nutzer berichteten Symptomverbesserung (Schmerz, Krämpfe, Muskelkrämpfe, Angst, Depression, Schlafstörungen, Libido, Reizbarkeit), aber 84% erlebten Nebenwirkungen (Mundtrockenheit, Schläfrigkeit, Rauschwirkung).
Zusammenfassung
n=274 Frauen mit chronischem Beckenschmerz (inkl. Endometriose-Subgruppe), anonyme Online-Umfrage; 61% berichten Cannabis-Nutzung zur Schmerz-Selbstbehandlung, subjektive Symptomlinderung bei Dysmenorrhoe und Dyspareunie; keine validierten Outcome-Messungen, keine Placebo-Kontrolle.
P
PopulationFrauen mit chronischem Beckenschmerz (CPP), Dyspareunie oder Endometriose, n=113 aus ambulanter gynäkologischer Praxis
I
InterventionSelbstverabreichtes Cannabis (verschiedene Applikationsformen, ≥1x/Woche bei 72% der Nutzerinnen)
O
Outcome23% (n=26) berichten Cannabis-Nutzung; 96% (n=24) davon geben Symptomverbesserung an (Schmerz, Krämpfe, Angst, Schlaf); 35% reduzierten Kontaktfrequenz zum Arzt
Qualitätsprofil
Größe
★★★★★
Verblindung
—
Effektstärke
Gemischt
Zitate / Jahr
★★★★★
Autoren
Teilen
Abstract
Background: Chronic pelvic pain (CPP) affects up to 15% of women in the United States. The endocannabinoid system is a potential pharmacological target for pelvic pain as cannabinoid receptors are highly expressed in the uterus and other nonreproductive tissues. We hypothesize that cannabis use is common for self-management of CPP, and our primary objective was to determine the prevalence of cannabis use in this population. Materials and Methods: A cross-sectional survey of women with pelvic and perineal pain, dyspareunia, or endometriosis was performed between March and August 2019. Subjects were recruited in an outpatient gynecology office. An anonymous, confidential, electronic survey was performed using a tablet. Statistical analysis was performed using JMP (SAS, Cary, NC). Results: A total of 240 patients were approached, with 113 responses (47.1% response rate). There were 26 patients who used cannabis (23%). The majority used at least once per week (n = 18, 72%). Most users (n = 24, 96%) reported improvement in symptoms, including pain, cramping, muscle spasms, anxiety, depression, sleep disturbances, libido, and irritability. Over one-third (35%) stated that cannabis use decreased the number of phone calls or messages sent to their provider, and 39% reported decreased number of clinical visits. Side effects, including dry mouth, sleepiness, and feeling "high," were reported by 84% (n = 21). Conclusions: Almost one-quarter of patients with CPP report regular use of cannabis as an adjunct to their prescribed therapy. Although side effects are common, most users report improvement in symptoms. Our study highlights the potential of cannabis as a therapeutic option for patients with CPP.
„Was dem Handeln im Weg steht, wird zum Weg.“